The Union government is reviewing a proposal to bring all sterile drug manufacturing under the Central Licence Approving Authority. This move follows a Supreme Court ruling that limited central inspection powers and aims to address quality concerns. Investors should note potential shifts in compliance costs and regulatory scrutiny for pharmaceutical companies.
The Union government is exploring a proposal to overhaul the regulatory framework for sterile drugs by bringing all such products under the Central Licence Approving Authority (CLAA). This initiative aims to establish a uniform standard for safety and microbial control across the country. The move comes as the government reassesses its enforcement capabilities following a Supreme Court decision that upheld a Himachal Pradesh High Court ruling, which restricted the powers of Central Drugs Standard Control Organisation (CDSCO) inspectors to enforce provisions under the Drugs and Cosmetics Act.
Currently, the regulation of pharmaceutical products is split between state and central authorities. While specific sterile categories like vaccines and large-volume parenterals are already monitored by the CLAA, many other injectable and ophthalmic preparations remain under state jurisdiction. This fragmented system has been a point of concern for regulators, particularly after reports indicated that approximately 240 injection samples were found to be not of standard quality (NSQ) during the 2025-26 fiscal year. By consolidating oversight, the government intends to eliminate variations in inspection standards and ensure that all manufacturers adhere to a singular, rigorous baseline.
The proposed change carries significant implications for the pharmaceutical sector. For companies, moving to a centralized licensing regime typically involves higher compliance requirements and more detailed documentation compared to some state-level processes. While this shift may enhance product safety and industry reputation in the long term, it could initially lead to operational adjustments. Smaller manufacturers, in particular, may face challenges in meeting these higher technical and quality control benchmarks, potentially leading to increased spending on facility upgrades.
Investors should monitor the transition process, as regulatory changes often involve periods of uncertainty. The government has formed a sub-committee under the Drugs Consultative Committee to assess the legal and practical feasibility of this centralization. Seeking a formal legal opinion before implementation is a critical step to avoid further friction between central and state regulatory authorities. During this phase, market participants may watch for potential delays in new product approvals or license renewals as the administrative frameworks are harmonized. The final impact on the industry will depend on the clarity of the new guidelines and the timeline for implementation once the legal committee concludes its review.